GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

March 30, 2024

Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
DRUG

GB491+ Fulvestrant

"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."

DRUG

Placebo+Fulvestrant

"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."

Trial Locations (54)

50011

The Fourth Hospital of Hebei Medical University, Shijiazhuang

100020

Beijing Chaoyang Hospital of Capital Medical University, Beijing

100021

Cancer hospital Chinese Academy of Medical Sciences, Beijing

100039

Chinese PLA General Hospital, Beijing

100050

Beijing Tiantan Hospital , Capital Medical University, Beijing

110022

Shengjing Hospital of China Medical University, Shenyang

110801

Liaoning Cancer hospital & Institute, Shenyang

130012

Jilin Cancer Hospital, Changchun

130041

The Second Hospital of Jilin University, Changchun

130061

Bethune First Hospital Of Jilin University, Changchun

150081

Harbin Medcial Univercity cancer hospital, Haerbin

200030

Zhongshan Hospital Fudan University, Shanghai

210029

Jiangsu Province Hospital, Nanjing

230031

Anhui Provincial Cancer Hospital, Hefei

230601

The Second Hospital of Anhui Medical University, Hefei

233099

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250013

Central Hospital Affiliated to Shandong First Medical University, Jinan

Shandong Provincial Qianfoshan Hospital, Jinan

250021

Shandong Provincial Hospital, Jinan

250117

Shandong Cancer Hospital, Jinan

252004

Liaocheng People's Hospital, Liaocheng

264099

Yantai Yuhuangding Hospital, Yantai

266003

The Affiliated Hospital of Qingdao University, Qingdao

271099

Taian City Central Hospital, Taian

272007

Affiliated hospital of Jining Medical University, Jining

300181

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310003

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310005

Zhejiang Cancer Hospital, Hangzhou

330029

Jiangxi Provincial Hospital, Nanchang

350001

Fujian Medical University Union Hospital, Fuzhou

361003

First Affiliated Hospital of Xiamen University, Xiamen

400030

Chongqing University Cancer Hospital, Chongqing

400042

The First Affiliated Hospital of Chongqing Medical University, Chongqing

404000

Chognqing University Three Gorges Hospital, Chongqing

430022

Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

430079

Hubei Cancer Hospital, Wuhan

450003

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

500311

Affiliated hospital of Hebei University, Shijiazhuang

510060

Sun Yat-sen University Cancer Center, Guangzhou

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510120

Guangdong provincial TCM hospital, Guangzhou

514031

Meizhou People's Hospital, Meizhou

518172

Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center Shenzhen Cancer Hospital, Shenzhen

528000

The First people's hospital of Foshan, Foshan

570311

Hainan General Hospital, Haikou

572000

Hainan Third People's Hospital, Sanya

610044

West China School of Medicine, Chengdu

650118

The Third Affiliated Hospital of Kunming Medical University, Kunming

750003

General Hospital of Ningxia Medical University, Yinchuan

750306

The Affiliated hospital of Inner Mongolia Medical University, Hohhot

830011

Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

003001

The first hospital of Shanxi Medical University, Taiyuan

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY